TORL BioTherapeutics
Los Angeles, United States · Biopharma, Biotechnology, Health Care
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for p
Key facts
- Headquarters
- Los Angeles, United States
- Employees
- 63
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- torlbio.com
- Company page
Recent activity at TORL BioTherapeutics
- : TORL BioTherapeutics Appoints Sandip Kapadia as Chief Financial Officer and Eric Sievers, M.D. as Chief Medical Officer
- : TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer
- : TORL BioTherapeutics secures $96M Series C financing to advance clinical development of TORL-1-23 for ovarian cancer.
- : TORL BioTherapeutics Appoints Aran Maree, MD, as Chief Medical Officer and Initiates Global Phase 2 Study of TORL-1-23
- : TORL BioTherapeutics
- : TORL BioTherapeutics closed an oversubscribed $158M Series B-2 financing round to advance clinical development of its novel antibody-drug conjugate oncology pipeline.
TORL BioTherapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Series C | $96.0M |
| Apr 2024 | Venture | $158.3M |
| Apr 2024 | Series B | $158.0M |
Leadership
- Tracey Marantal, Senior Vice President, Clinical Operations
- Eric Sievers, M.D., Chief Medical Officer
- Sandip Kapadia, Chief Financial Officer
- Christine Loggins, Chief Operating Officer
- Aran Maree, M.D., Chief Executive Officer
- Dave Licata, President
- Aran Maree, Chief Medical Officer
- Lee Sailor, Chief Administrative Officer
Verified email and direct lines for TORL BioTherapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
TORL BioTherapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
TORL BioTherapeutics in the news
- TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress - BioSpace (Sep 16, 2024)
- TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress - PR Newswire (Oct 07, 2025)
- TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026 - PR Newswire (Jun 18, 2026)
- TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline - PR Newswire (Apr 10, 2024)
- TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs - PR Newswire (Jan 09, 2024)
Companies similar to TORL BioTherapeutics
- BridgeBio Oncology Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apollomics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Day One Biopharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About TORL BioTherapeutics: questions and answers
What does TORL BioTherapeutics do?
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for p
Where is TORL BioTherapeutics headquartered?
TORL BioTherapeutics is headquartered in Los Angeles, United States.
How many employees does TORL BioTherapeutics have?
TORL BioTherapeutics has about 63 employees.
Has TORL BioTherapeutics raised funding?
Yes. Fundz has recorded 3 funding events for TORL BioTherapeutics. The most recent, Series C of $96.0M, was in Oct 2025.
Who leads TORL BioTherapeutics?
Tracey Marantal is a Senior Vice President, Clinical Operations at TORL BioTherapeutics.
What is the latest news on TORL BioTherapeutics?
On Oct 16, 2026, TORL BioTherapeutics Appoints Sandip Kapadia as Chief Financial Officer and Eric Sievers, M.D. as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy